



Matthew Frank

Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplant Program**

269 W Campus Dr CCSR 2205

Stanford, CA 94305

Tel (650) 498-8886 Fax (650) 725-3321

Bio

BIO

Dr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR) T therapy for patients with lymphomas and leukemias. Dr. Frank's research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Medical Education: UCLA David Geffen School Of Medicine (2011) CA
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2019) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2018) CA
- Residency: Beth Israel Deaconess Medical Center Internal Medicine Residency (2013) MA
- PhD, Department of Pathology and Laboratory Medicine at UCLA , Cellular and Molecular Pathology (2009)
- BS, Massachusetts Institute of Technology , Electrical Engineering (2003)

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting

- Phase I B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme, Recruiting
- Phase Ib Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in w/ Recurrent/Refractory B Cell Lymphomas, Recruiting
- Phase I/Ib Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies, Not Recruiting
- Phase Ib Axicabtagene Ciloleucef Reinfusion (Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL, Not Recruiting
- Phase II CRG-022 - CD22-Directed Autologous CAR T-Cell Tx in Relapsed/Refractory Large B-Cell Lymphoma, Not Recruiting
- Phase III Axicabtagene Ciloleucef vs Standard of Care Therapy in Relapsed/Refractory Follicular Lymphoma, Not Recruiting
- Phase tbd Long-Term Cognitive Neuropsychiatric & Functional Outcomes in CAR-T Tx in Aggressive Lymphoma, Not Specified

Publications

PUBLICATIONS

- **Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.** *Blood cancer discovery*
Srinagesh, H. K., Kramer, A. M., Baird, J. H., Reschke, A., Sahaf, B., Cancilla, J., Syal, S., Su, Y. J., Agarwal, N., Jensen, A. M., Schultz, L. M., Jeyakumar, N., Ramakrishna, et al
2025
- **Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.** *Cancer discovery*
Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, et al
2025
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).** *Transplantation and cellular therapy*
Hines, M. R., Knight, T. E., Mc Nerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, et al
2023
- **Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.** *Cancer cell*
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Shahrokh Esfahani, M., Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M., Spiegel, et al
2022
- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al
AMER SOC HEMATOLOGY.2021
- **Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucef Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A. P., Mullins, C. D., Lee, L. W., Kong, K. A., Craig, J., Mackall, et al
2021: JCO2100377
- **Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.** *American journal of hematology*
Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., Kirsch, I., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Miklos, D., Frank, et al
2026

- **Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucl to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia**
Jeyakumar, N., Shiraz, P., Weber, E., Kanegai, A., Wagner, C., Ramakrishnan, A., Sahaf, B., Frank, M., Dahiya, S., Smith, M., Sidana, S., Mackall, C., Miklos, et al
AMER ASSOC CANCER RESEARCH.2026
- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
2026
- **Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucl Toxicity Reduces the Total Duration of CRS and ICANS.** *Blood advances*
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., Hamilton, M. P., Ghalehsari, N., Latchford, T., Scott, B. J., Mallampet, J., Heng, E., Khan, et al
2026
- **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucl and Brexucabtagene Autoleucl for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al
ELSEVIER SCIENCE INC.2026: S27
- **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
ELSEVIER SCIENCE INC.2026
- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
ELSEVIER SCIENCE INC.2026
- **AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T**
Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilineni, L., Sidana, S., Weng, W., Frank, M., Dahiya, S., Smith, M., Chaudhari, A., Miklos, D. B., Boutin, et al
ELSEVIER SCIENCE INC.2026
- **Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.** *Leukemia & lymphoma*
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., Schroers-Martin, J., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D., Dahiya, S., Binkley, et al
2025: 1-8
- **Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucl**
Tun, A., Frank, M., Iqbal, M., Herrera, A., Hamadani, M., Perez, W., Kim, S., Adedokun, B., Lau, C., Hu, K., Best, T., Nikolajeva, O., Lee, et al
ELSEVIER.2025: 5356-5357
- **CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma**
Kramer, A., Murty, T., Chen, Y., Rodrigues, K., Hamilton, M., Desai, M., Kuo, A., Ehlinger, Z., Reynolds, W., Srinagesh, H., Tsui, K., Rietberg, S., Mo, et al
ELSEVIER.2025: 566-567
- **Firicabtagene autoleucl (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)**

Frank, M., Qualls, D., Ghobadi, A., Gauthier, J., Tees, M., Mountjoy, L., Mcguirk, J., Neelapu, S., Karmali, R., Isufi, I., Hill, B., Sauter, C., Diefenbach, et al
ELSEVIER.2025: 667-668

- **Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (rLBCL): Interim results from a Phase 1b study**
Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al
ELSEVIER.2025: 671-672
- **Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL**
Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D., Nguyen-Mau, S., Kong, K., Bornheimer, S., Mikkilineni, L., Muffly, L., Sidana, S., Weng, W., Bharadwaj, et al
ELSEVIER.2025: 5882-5883
- **Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results**
Schultz, L., Aftandilian, C., Baggott, C., Corwin, N., Fujimoto, M., Li, A., Mavroukakis, S., Moon, J., Sahaf, B., Jacobs, A., Mendoza, C., Levenson, A., Frank, et al
ELSEVIER.2025: 2374
- **Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study**
Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, et al
ELSEVIER.2025: 111-112
- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al
ELSEVIER.2025: 2494-2495
- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**
Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
ELSEVIER.2025: 4159-4160
- **Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma**
Lee, J., Jensen, A., Hosoya, H., Afrough, A., Zanwar, S., Pasvolosky, O., Gaballa, M., Dillard, C., Khouri, J., Raza, S., Goel, U., Anwer, F., Hovanky, et al
ELSEVIER.2025: 719-720
- **Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)**
Lee, J., Jensen, A., Hosoya, H., Zanwar, S., Pasvolosky, O., Gaballa, M., Dillard, C., Khouri, J., Raza, S., Goel, U., Anwer, F., Hovanky, V., Rana, et al
ELSEVIER.2025: 717-718
- **Redefining post-CD19 CAR T-cell surveillance with ctDNA: Real-world insights from post- axi-cel and liso-cel therapy**
Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., Serrato, J., Kirsch, I., Jacob, A., Simmons, H., Lee, L., Mackall, C., Weng, et al
ELSEVIER.2025: 941-942
- **Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy**
Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Park, N., Goyal, A., Hashmi, A., Wang, W., Heng, E., Velayati, A., Dhapola, G., Huang, Y., Sahaf, et al
ELSEVIER.2025: 397-398
- **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
Jayakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al

ELSEVIER.2025: 2525-2526

- **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al
ELSEVIER.2025: 514-515
- **From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL**
Velayati, A., Rana, M., Jensen, A., Lee, D., Ghalehsari, N., Goyal, A., Latchford, T., Wang, W., Heng, E., Weng, W., Smith, M., Bharadwaj, S., Frank, et al
ELSEVIER.2025: 2771-2772
- **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
- **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. *Research square***
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
2025
- **Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome>[*Transplant Cell Ther.* 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>. *Transplantation and cellular therapy***
Hines, M. R., Knight, T. E., McNERney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, et al
2025
- **Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. *Cytotherapy***
Dreyzin, A., Kramer, A. M., Yates, B., Wang, H. W., Sahaf, B., Yuan, C., Klysz, D., Tunuguntla, R., Ehlinger, Z., Reitberg, S., Adebola, S., Su, A., Ebina-Shibuya, et al
2025: 101990
- **Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma**
Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., Bennett, L., Latchford, T., Arai, S., Bharadwaj, S., Frank, M., Dahiya, S., Muffly, et al
CIG MEDIA GROUP, LP.2025
- **Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. *Blood advances***
Epstein-Peterson, Z. D., Lionel, A. C., Joseph, A., Drill, E., Atallah-Yunes, S. A., Brooks, T. R., Chong, E. A., Chong, E. R., Dela Cruz, J., Frank, M. J., Ip, A., Iqbal, M., Jacobson, et al
2025
- **Real-world outcomes of brexucabtagene autoleucl for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. *Blood advances***
Ahmed, N., Thiruvengadam, S., Hamadani, M., Hu, Z. H., Grover, N. S., Shadman, M., Locke, F. L., Gerson, J., Frank, M. J., Budde, L. E., Wang, M. L., Kim, S., Bye, et al
2025
- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy. *Blood advances***
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025
- **Lisocabtagene Maraleucl for Richter's Transformation-A Case Series. *EJHaem***
Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., Smith, M., Frank, M., Dahiya, S., Miklos, D., Bharadwaj, S.
2025; 6 (2): e270011
- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease. *Blood***

- Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
- **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. *Bone marrow transplantation***
Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al
2024
 - **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucl Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
 - **Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes**
Noordenbos, T., Schroers-Martin, J. G., Hamilton, M. P., Jun, S., Sugio, T., Sworder, B. J., Steen, C., Olsen, M., Liu, C., Newman, A., Howitt, B., Natkunam, Y., Miklos, et al
ELSEVIER.2024: 2993-2994
 - **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
 - **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
 - **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
 - **Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis**
Epstein-Peterson, Z. D., Lionel, A. C., Joseph, A., Drill, E., Atallah-Yunes, S., Brooks, T. R., Chong, E. A., Chong, E. R., Dela Cruz, J., Frank, M. J., Ip, A., Iqbal, M., Jacobson, et al
ELSEVIER.2024: 239-240
 - **CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)**
Kramer, A., Murty, T., Chen, Y., Srinagesh, H., Hamilton, M. P., Mo, K. C., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., Reynolds, W. D., Baird, J. H., Su, et al
ELSEVIER.2024: 911-912
 - **Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes**
Noordenbos, T., Schroers-Martin, J. G., Hamilton, M. P., Jun, S., Sugio, T., Sworder, B. J., Steen, C., Olsen, M., Liu, C., Newman, A., Howitt, B., Natkunam, Y., Miklos, et al
ELSEVIER.2024: 2993-2994
 - **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
 - **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al

ELSEVIER.2024: 70-71

- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis**
Epstein-Peterson, Z. D., Lionel, A. C., Joseph, A., Drill, E., Atallah-Yunes, S., Brooks, T. R., Chong, E. A., Chong, E. R., Dela Cruz, J., Frank, M. J., Ip, A., Iqbal, M., Jacobson, et al
ELSEVIER.2024: 239-240
- **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.** *Blood cancer journal*
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
2024; 14 (1): 173
- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
SPRINGER NATURE.2024: 287-288
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.** *The New England journal of medicine*
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., Frank, M. J., Sahaf, B., Mackall, et al
2024; 390 (22): 2047-2060
- **Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.**
Ghobadi, A., Jacobson, C., McGuirk, J., Shah, N., Rossi, J., Buchholz, T., Bachier-Rodriguez, L., Baird, J. H., Diefenbach, C. S., Farooq, U., Hernandez-Ilizaliturri, F. J., Isufi, I., Patel, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series.** *Haematologica*
Scala, J. J., Eckrich, M. J., Lipak, K., Yates, B., Yuan, C., Wang, H. W., Dahiya, S., Henter, J. I., Huo, J. S., Frank, M. J., Shah, N. N.
2024
- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024

- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
2024
- **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
2024
- **CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL** *American Society of Hematology*
Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., Reynolds, W. D., Yang, E., Ozawa, M. G., Chen, Y., Prabhu, S., Frank, M. J., Muffly, et al
2024
- **Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas.** *Blood advances*
Shukla, N., Schroers-Martin, J., Sworder, B., Kathuria, K. R., Alig, S., Frank, M. J., Miklos, D. B., Coutre, S. E., Diehn, M., Khodadoust, M. S., Roschewski, M. J., Kurtz, D. M., Alizadeh, et al
2023
- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
2023
- **A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.** *Blood advances*
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L., Alizadeh, A. A., Advani, R. H., Hoppe, R. T., Long, et al
2023
- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
- **Comparative Effectiveness of Axicabtagene Ciloleucef Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data**
Kambhampati, S., Wang, H., Yan, J., Herrera, A. F., Frank, M. J., Popplewell, L. L., Ahmed, N., Lin, Y., Locke, F. L., Ghione, P., Gribben, J. G., Best, T., Fu, et al
AMER SOC HEMATOLOGY.2023
- **Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)**
Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., Hana, C., Chavez, J. C., Ionescu, F., Frank, M. J., Bharadwaj, S., Sandoval-Sus, J., Beitinjaneh, et al
AMER SOC HEMATOLOGY.2023
- **CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN- Cytokine Signature**
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y., Kramer, A., Reschke, A., Jeyakumar, N., Bharadwaj, S., Schultz, L., Ramakrishna, S., Davis, K. L., Sahaf, B., Feldman, et al
AMER SOC HEMATOLOGY.2023
- **Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible**
Su, Y., Kramer, A., Hamilton, M. P., Agarwal, N., Feldman, S., Sahaf, B., Kuo, A., Mackall, C. L., Muffly, L. S., Miklos, D. B., Frank, M. J.
AMER SOC HEMATOLOGY.2023
- **Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL**
Kramer, A., Hamilton, M. P., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., Agarwal, N., Su, Y., Gkitsas, N., Fowler, C., Keerthi, V., Retherford, A., Klysz, et al

AMER SOC HEMATOLOGY.2023

- **Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)**
Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., Sahaf, B., Syal, S., Patil, S., Cancilla, J. E., Latchford, T., Weng, W., Smith, et al
AMER SOC HEMATOLOGY.2023
- **Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., Syal, S., Mallampet, J., Latchford, T., Sahaf, B., Weng, W., Smith, M., Maecker, et al
AMER SOC HEMATOLOGY.2023
- **Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection**
Ananth, S., Su, Y., Hamilton, M. P., Agarwal, N., Weng, W., Dahiya, S., Bharadwaj, S., Mallampet, J., Smith, M., Kong, K., Twoy, A., Miklos, D. B., Frank, et al
AMER SOC HEMATOLOGY.2023
- **Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., Marar, M., Lee, C., Ananth, S., Sahaf, B., Mallampet, J., Ehlinger, Z., Syal, et al
AMER SOC HEMATOLOGY.2023
- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. *Blood cancer journal***
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
2023; 13 (1): 158
- **Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc***
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., Majzner, R. G., Miklos, D. B., Frank, M. J., Natkunam, Y.
2023: 100256
- **Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.**
Kambhampati, S., Ahmed, N., Hamadani, M., Grover, N., Shadman, M., Locke, F. L., Gerson, J. M., Frank, M., Budde, L., Wang, M., Hu, Z., Nunes, A., Dalton, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).**
Jacobson, C., Hemmer, M. T., Hu, Z., Frank, M., Popplewell, L., Ahmed, N., Lin, Y., Best, T., Beygi, S., Miao, H. H., Fu, C., Sun, F., Xu, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma. *Blood advances***
Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., Dahiya, S., Miklos, D. B., Altrock, P. M., Locke, F. L.
2023
- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. *Blood***
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
2023
- **Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology***

Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., Vose, J. M., Goy, A., Andreadis, et al
2023: JCO2201797

- **Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.** *Journal of neuropathology and experimental neurology*
Nie, E. H., Ahmadian, S. S., Bharadwaj, S. N., Acosta-Alvarez, L., Threlkeld, Z. D., Frank, M. J., Miklos, D. B., Monje, M., Scott, B. J., Vogel, H.
2023
- **Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS**
Shukla, N. D., Schroers-Martin, J., Kathuria, K. R., Sworder, B., Alig, S. K., Frank, M. J., Miklos, D. B., Coutre, S., Diehn, M., Khodadoust, M. S., Roschewski, M., Kurtz, D. M., Alizadeh, et al
AMER SOC HEMATOLOGY.2022: 6403-6404
- **Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease**
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., Rezvani, A. R., Frank, M. J., Bharadwaj, S., Weng, W., Negrin, R. S., Miklos, D. B., Arai, et al
AMER SOC HEMATOLOGY.2022: 4788-4789
- **Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era**
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Bharadwaj, S., Frank, et al
AMER SOC HEMATOLOGY.2022: 4825-4827
- **Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation**
Schultz, L. M., Ramakrishna, S., Baskar, R., Richards, R. M., Moon, J., Baggott, C., Fujimoto, M., Kunicki, M., Li, A., Jariwala, S., Erickson, C., Jacobs, A., Yamabe, et al
AMER SOC HEMATOLOGY.2022: 10300-10302
- **Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy**
Boegeholz, J., Alig, S. K., Sworder, B., Schroers-Martin, J., Macaulay, C., Craig, A. F. M., Duehrsen, U., Huettmann, A., Westin, J., Cherng, H. J., Miklos, D. B., Frank, M. J., Diehn, et al
AMER SOC HEMATOLOGY.2022: 8609-8610
- **Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma**
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., Advani, R. H., Hoppe, R., Long, et al
AMER SOC HEMATOLOGY.2022: 6450-6451
- **Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study**
Scott, B. J., Murray, T., Deutsch, G. K., Lahijani, S., Frank, M. J., Monje, M.
AMER SOC HEMATOLOGY.2022: 5201-5202
- **CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study**
Jeyakumar, N., Ramakrishna, S., Frank, M. J., Sahaf, B., Feldman, S. A., Miklos, D. B., Mackall, C. L., Davis, K. L., Muffly, L., Schultz, L. M.
AMER SOC HEMATOLOGY.2022: 2374-2375
- **A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (gamma delta) T Cells in Adults with B-Cell Malignancies**
Neelapu, S. S., Stevens, D. A., Hamadani, M., Frank, M. J., Holmes, H., Jacobovits, A., Hinkle, J., Kennedy-Wilde, J., Maller, O., Weinstein, B., Galimi, F., Lai, R. K., Miklos, et al
AMER SOC HEMATOLOGY.2022: 4617-4619
- **Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas**
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., Macaulay, C., Esfahani, M., Olsen, M., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, et al
AMER SOC HEMATOLOGY.2022: 1301-1303

- **CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study**
Jeyakumar, N., Ramakrishna, S., Frank, M. J., Sahaf, B., Feldman, S. A., Miklos, D. B., Mackall, C. L., Davis, K. L., Muffly, L., Schultz, L. M.
AMER SOC HEMATOLOGY.2022: 2374-2375
- **A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (gamma delta) T Cells in Adults with B-Cell Malignancies**
Neelapu, S. S., Stevens, D. A., Hamadani, M., Frank, M. J., Holmes, H., Jacobovits, A., Hinkle, J., Kennedy-Wilde, J., Maller, O., Weinstein, B., Galimi, F., Lai, R. K., Miklos, et al
AMER SOC HEMATOLOGY.2022: 4617-4619
- **Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas**
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., Macaulay, C., Esfahani, M., Olsen, M., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, et al
AMER SOC HEMATOLOGY.2022: 1301-1303
- **Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy** *NATURE MEDICINE*
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Lin, A., Vandris, P., Wu, F., Prabhu, S., Hamilton, et al
2022
- **Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome.** *JAMA oncology*
Butt, O. H., Zhou, A. Y., Caimi, P. F., Lockett, P. H., Wisch, J. K., Derenoncourt, P., Lee, K., Wu, G. F., de Lima, M. J., Campian, J. L., Frank, M. J., DiPersio, J. F., Ghobadi, et al
2022
- **CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse.** *Blood advances*
Vu, K., Frank, M. J.
2022
- **Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma**
Good, Z., Hamilton, M. P., Spiegel, J. Y., Kurra, S., Desai, M., Prabhu, S., Yang, E., Ozawa, M. G., Hanson, P. J., Wu, F., Frank, M. J., Baird, J. H., Muffly, et al
AMER ASSOC CANCER RESEARCH.2022
- **Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.**
Jain, P., Wang, Y., Locke, F. L., Munoz, J., Beitinjaneh, A., Frank, M., Dahiya, S., Jacobs, M. T., Hill, B. T., Lekakis, L. J., Miklos, D., Ghobadi, A., Neelapu, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy**
Nie, E., Ahmadian, S., Bharadwaj, S., Acosta-Alvarez, L., Threlkeld, Z., Frank, M., Miklos, D., Born, D., Scott, B., Monje, M., Vogel, H.
OXFORD UNIV PRESS INC.2022: 464
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
- **Inferring gene expression from cell-free DNA fragmentation profiles.** *Nature biotechnology*
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., Soo, J., Schroers-Martin, J. G., Chen, et al
2022
- **Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance**
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., Frank, M., Miklos, D., Natkunam, Y.
SPRINGER NATURE.2022: 1046-1048

- **Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance**
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., Frank, M., Miklos, D., Natkunam, Y.
SPRINGER NATURE.2022: 1046-1048
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800
- **Mgta-145+Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
AMER SOC HEMATOLOGY.2021
- **ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T**
Neelapu, S. S., Nath, R., Munoz, J., Tees, M., Miklos, D. B., Frank, M. J., Malik, S. A., Stevens, D., Shin, C., Balakumaran, A., Loomis-Navale, L., Goyal, L., Nguyen, et al
AMER SOC HEMATOLOGY.2021
- **ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing**
Lekakis, L. J., Locke, F. L., Tees, M., Neelapu, S. S., Malik, S. A., Hamadani, M., Frank, M. J., Popplewell, L. L., Abramson, J. S., Vos, S., Munoz, J., Shi, C., Balakumaran, et al
AMER SOC HEMATOLOGY.2021
- **Brexucabtagene Autoleucl for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium**
Wang, Y., Jain, P., Locke, F. L., Munoz, J., Maurer, M. J., Beitinjaneh, A., Frank, M. J., Dahiya, S., McGuirk, J. P., Jacobs, M. T., Goy, A. H., Vose, J. M., Hill, et al
AMER SOC HEMATOLOGY.2021
- **Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study**
Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., Thiengmany, A., Frank, M. J., Miklos, D. B., Shah, N. N., D'Souza, A., Knight, J. M., Muffly, et al
AMER SOC HEMATOLOGY.2021
- **Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy**
Tan, I., Cusatis, R., Crawford, E., Thiengmany, A., Piehowski, C., Akinola, I., Craig, J., Lahijani, S., Frank, M. J., Shah, N. N., D'Souza, A., Miklos, D. B., Muffly, et al
AMER SOC HEMATOLOGY.2021
- **Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation**
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., Frank, M. J., Beygi, S., Hoppe, R., Long, S. R., Martin, B., Ji, H. P., Levy, et al
AMER SOC HEMATOLOGY.2021
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151

- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
SPRINGER NATURE.2021: 181
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143-155
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143-55
- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
2021
- **Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.** *Cancer cytopathology*
Mooney, K. L., Czerwinski, D. K., Shree, T., Frank, M. J., Haebe, S., Martin, B. A., Testa, S., Levy, R., Long, S. R.
2021
- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al

2020

- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
Lemieux, C., Muffy, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffy, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. *The Journal of experimental medicine***
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells. *Cytotherapy***
Frank, M. J., Olsson, N. n., Huang, A. n., Tang, S. W., Negrin, R. S., Elias, J. E., Meyer, E. H.
2020; 22 (3): 135–43
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. *Blood***
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. *Bone marrow transplantation***
Lemieux, C. n., Muffy, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
- **Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma**
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., Guo, S., Long, S., Martin, B. A., Levy, R.
AMER ASSOC CANCER RESEARCH.2019
- **Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.**
Frank, M., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A., Mullins, C. D., Lee, L., Kong, K. A., Craig, J. K., Mackall, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy**
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., Guo, X., Shree, T., Greenstein, R.
NATURE PUBLISHING GROUP.2019
- **Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy**
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., Guo, X., Shree, T., Greenstein, R.
NATURE PUBLISHING GROUP.2019
- **Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
- **Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies**
Hossain, N., Sahaf, B., Abramian, M., Spiegel, J. Y., Kong, K., Kim, S., Mavroukakis, S., Oak, J., Natkunam, Y., Meyer, E. H., Frank, M. J., Feldman, S. A., Long, et al

AMER SOC HEMATOLOGY.2018

- **In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.** *Cancer discovery*
Frank, M. J., Reagan, P. M., Bartlett, N. L., Gordon, L. I., Friedberg, J. W., Czerwinski, D. K., Long, S. R., Hoppe, R. T., Janssen, R. S., Candia, A. F., Coffman, R. L., Levy, R.
2018
- **SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial**
Levy, R., Reagan, P. M., Friedberg, J. W., Bartlett, N. L., Gordon, L. I., Leung, A., Peterkin, J., Xing, B., Coffman, R., Janssen, R., Candia, A., Khodadoust, M., Frank, et al
AMER SOC HEMATOLOGY.2016
- **Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cytometry in Previously Untreated Patients**
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Kardosh, A., Okada, A., Robinson, S., Levy, R.
AMER SOC HEMATOLOGY.2016
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN**
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Chu, M. P., Okada, A., McDonald, K. A., Kohrt, H. E., Bartlett, N. L., Reagan, P. M., Friedberg, J. W., Gordon, L. I., Coffman, et al
AMER SOC HEMATOLOGY.2015
- **Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress.** *The American journal of pathology*
Balatoni, C. E., Dawson, D. W., Suh, J., Sherman, M. H., Sanders, G., Hong, J. S., Frank, M. J., Malone, C. S., Said, J. W., Teitell, M. A.
2009; 175 (4): 1653-61
- **Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.** *Blood*
Frank, M. J., Dawson, D. W., Bensinger, S. J., Hong, J. S., Knosp, W. M., Xu, L., Balatoni, C. E., Allen, E. L., Shen, R. R., Bar-Sagi, D., Martin, G. R., Teitell, M. A.
2009; 113 (11): 2478-87
- **High throughput cell nanomechanics with mechanical imaging interferometry** *NANOTECHNOLOGY*
Reed, J., Frank, M., Troke, J. J., Schmit, J., Han, S., Teitell, M. A., Gimzewski, J. K.
2008; 19 (23)